Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Caverion to deliver building solutions for new chalets in Himos, ski destination in Central Finland

Caverion Corporation Investor News 8 April 2024 at 10:00 EETCaverion to deliver building solutions for new chalets in Himos, ski destination in Central Finland The Finnish retail chain Osuuskauppa Keskimaa has selected Caverion to implement the building solutions for the holiday apartments and restaurant to be built in Himos, Central Finland. [Image: Arkkitehtipalvelu] "Our services being built at Himos will definitely attract more people to visit Himos and increase tourism in Central Finland. The project will also have a very significant impact on employment in the current downturn

Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the Company has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application no. 16/760,910 entitled “Use of NOX Inhibitors for Treatment of Cancer”.  This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.The allowed claims cover a method of treating a solid tumor presenting resistance to PD-1 inhibitor immunotherapy by administering setanaxib in combination with a PD-1

MapsPeople A/S Renews customer contract with large expansion in contract value

MapsPeople A/S | Investor News Aalborg, April 8, 2024 Early contract renewal with significant upsell MapsPeople A/S is pleased to announce the signing of a large expansion contract with a North American customer for an additional 39 months period for a smart building project containing up to 130 properties and up to 85 million square feet of residential real estate to be mapped. The contract expansion is mDKK 5.2 for the contracted period. The new annual recurring revenue of this contract is below the mDKK 2.0 threshold that requires a company announcement according to MapsPeople

DonkeyRepublic Holding A/S carries out a private placement

*Contains inside information*Company announcement No. 5 – 2024  DonkeyRepublic Holding A/S has successfully completed an oversubscribed private placement of new shares to existing investors at a subscription price of DKK 6.33 per share, raising gross proceeds of DKK 22.4M.  This private placement aligns with the company's strategic goals outlined in the 2023 annual report, where it signaled intentions to explore capital-raising opportunities to bolster B2G growth initiatives through long-term contracts with cities beyond 2024. The newly secured funds are intended to strengthen the

Repurchase of Truecaller B shares in week 14, 2024

During 2 April 2024 and 5 April 2024 Truecaller AB (publ) (LEI code 549300TEYF1FA5G5GK26) has repurchased in total 742,544 own B shares (ISIN: SE0016787071) as part of the share buyback programme initiated by the board of directors. The buybacks are now temporarily halted, in accordance with applicable rules, ahead of the interim report for January-March 2024 which will be published on the 7th of May.The share buybacks form part of the share buyback programme announced by Truecaller on 7 June 2023. The share buyback programme will run between 7 June up until the 2024 AGM which will be held

Notice to the Annual General Meeting

Tele2 AB (publ), Reg. No. 556410-8917, with its registered office in Stockholm, Sweden, hereby gives notice to attend the Annual General Meeting on Wednesday 15 May 2024 at 15.00 CEST at Operaterrassen, Karl XII:s torg 1, in Stockholm. The doors open for shareholders at 14.15 CEST.Right to participate in the Annual General Meeting and notice of participation   A shareholder may participate in the Annual General Meeting at the venue (in person or represented by a proxy) or through advance voting (postal voting).   Participation in the Annual General Meeting at the venue   A

Notice to extraordinary general meeting in Scibase Holding AB (publ)

Shareholders of SciBase Holding AB (publ), reg. no. 556773-4768 (the "Company"), are hereby summoned to an extraordinary general meeting to be held on 13 May 2024 at 09.00 CEST at Advokatfirman Schjødt, Hamngatan 27, in Stockholm. The registration to the meeting will open at 08.30 CEST.This notice is a translation of a Swedish notice and in case of any deviations between the language versions, the Swedish version shall prevail. Right to participate and notice of participation A shareholder who wishes to participate at the extraordinary general meeting must: (i) be recorded in the

Gaming Innovation Group: The Nomination Committee's proposal for election of Board members 2024

Gaming Innovation Group Inc. (“GiG”) advances according to plan with its strategic split of its Media and Platform businesses by distributing GiG Platform to its shareholders. As part of this process, the nomination committee of GiG (the “Nomination Committee”) has reviewed and evaluated two separate board compositions with the aim to optimise the growth opportunities for each business entity.   GiG Media will continue to operate under GiG’s current corporate structure, with GiG serving as its listed holding company. GiG Platform, currently operated as a subsidiary of GiG, will be spun

President and CEO Martin Lindqvist is leaving SSAB

After 26 years in the company and 13 years as President and CEO, Martin Lindqvist has decided to leave SSAB to further his board career. A recruitment process to find his replacement will start immediately. Martin Lindqvist has been employed at SSAB since 1998 and served as the company’s President and CEO since 2011. Under his leadership, SSAB completed the acquisition of Finnish company Rautaruukki. In 2016, work began to transform the steel industry to fossil-free production through HYBRIT, a joint venture between SSAB, LKAB and Vattenfall. SSAB has since then taken a policy

Tokmanni Group Corporation: Managers' Transactions – Tapio Arimo

Tokmanni Group Corporation        Managers' Transactions        8 April 2024 at 9:20 amPerson subject to the notification requirementName: Tapio ArimoPosition: Chief Financial OfficerIssuer: Tokmanni Group OyjLEI: 743700VMG6KWF0FW1560Notification type: INITIAL NOTIFICATIONReference number: 57578/5/4 Transaction date: 2024-03-22Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI4000197934Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details(1): Volume: 1491 Unit price: 0 EUR Aggregated transactions (1):Volume: 1491 Volume

Tokmanni Group Corporation: Managers' Transactions – Mika Rautiainen

Tokmanni Group Corporation        Managers' Transactions        8 April 2024 at 9:10 amPerson subject to the notification requirementName: Mika RautiainenPosition: Chief Executive OfficerIssuer: Tokmanni Group OyjLEI: 743700VMG6KWF0FW1560Notification type: INITIAL NOTIFICATIONReference number: 57575/4/4 Transaction date: 2024-03-22Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI4000197934Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details(1): Volume: 4821 Unit price: 0 EUR Aggregated transactions (1):Volume: 4821

Approval of Warrant Terms and Conditions

Faron Pharmaceuticals Oy(“Faron” or “Company”)   Approval of Warrant Terms and Conditions   Company announcement, April 8, 2024 at 12:10 AM (EDT) / 7:10 AM (BST) / 9:10 AM (EEST)   TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today announces that the Board of Directors of Faron has approved the terms and conditions of the remaining 832,934

Decisions of the Board of Directors

Faron Pharmaceuticals Oy (“Faron or the “Company”) Decisions of the Board of Directors Company announcement, April 8, 2024 at 9:05 (EEST) / 7:05 AM (GMT) / 12:05 AM (EDT)   TURKU, FINLAND / BOSTON, MA - The annual general meeting ("AGM") of Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON) took place on April 5, 2024 and after the AGM, the Board of Directors ("Board") convened.   Frank Armstrong and Erik Ostrowsi did not stand for re-election and thus their tenure in the Company Board of Directors ended at the end of the AGM on 5 April, 2024.   At the meeting

AFRY awarded a new large-scale solar power assignment in the Philippines

Amatera Renewable Energy Corporation has appointed AFRY as the owner’s engineer for the construction of a 65MWp solar photovoltaic (PV) plant and its electrical interconnection. The project will provide clean energy to the City of Bacolod in the Philippines.Amatera Renewable Energy Corporation (ARECO) is a Philippine-based company undertaking a utility-scale solar power project called The Vista Alegre, a ground-mounted solar PV installation that will be located in Bacolod, the capital city of the island of Negros. ARECO is now part of B.Grimm Solar Power Inc., a subsidiary of B.Grimm Power,

Richard Sjöberg new Head of Communications at AcadeMedia

Richard Sjöberg has been appointed Head of Communications and member of the executive management team at AcadeMedia. He will assume the position on 15 April 2024. - Communication is important for an education company like AcadeMedia, where the work we do every day affects and engages many people. Welcoming Richard to AcadeMedia and Group Management is part of our efforts to strengthen our communication. We strive to be a strong and wise voice that can help shape solutions to challenges facing the education sector. Richard's experience and expertise will be very valuable in this work,

Enhertu approved in US for HER2+ solid tumours

08 April 2024 Enhertu approved in the US as first tumour-agnostic HER2-directed therapyfor previously treated patients with metastatic HER2-positive solid tumours Based on three Phase II trials of AstraZeneca and Daiichi Sankyo's Enhertu which showedclinically meaningful responses across a broad range of tumours Enhertu now has five approved indications with the latest in HER2-expressing(IHC 3+) metastatic cancers AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic

Net Asset Value(s)

RIZE SUSTAINABLE FUTURE OF FOOD UCITS ETF (LEI: 635400XEUXEEYJDGAN37) Final Net Asset Value FUND NAME NAV ISIN NAV DATE RIZE SUSTAINABLE 3.9989 USD IE00BLRPQH01 05 April 2024FUTURE OF FOOD UCITS ETF RIZE CYBER SECURITY AND DATA PRIVACY UCITS ETF (LEI: 635400X9AIBDQQ6PQR51) Final Net Asset Value FUND NAME NAV­ ISIN NAV DATERIZE CYBER SECURITY AND 7.3671 USD IE00BJXRZJ40 05 April 2024DATA PRIVACY UCITS ETF RIZE DIGITAL PAY ECONOMY ETF (LEI: LEI 635400LYAWYIKLU7RN49) Final

Application submitted to include an additional terbinafine supplier

STOCKHOLM, April 8[th], 2024, Moberg Pharma AB (OMX:MOB) has submitted an application to include the proposed terbinafine supplier in the company's registration dossier for its nail fungus drug MOB-015. Approval is expected before the end of the year.Together with its intended terbinafine supplier, Moberg Pharma has submitted an application to add the manufacturer for MOB-015. In addition, Moberg Pharma is actively working to secure an additional terbinafine supplier and thus has two parallel tracks to ensure a stable long-term supply of terbinafine. "The submission of the application to

Getinge invites fund managers, analysts, and media to Q1 Report 2024 conference call

Getinge will issue its Q1 Report 2024 on April 22, 2024, at 12:00 p.m. CEST, followed by a conference call at 13:00-14.00 p.m. CEST, hosted by Mattias Perjos, President & CEO, and Agneta Palmér, CFO.Fund managers, analysts and media are invited to participate in the conference call. To participate via teleconference, please register via this link . After registration, you will be provided with telephone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.

The subscription period in Diagonal Bio AB rights issue commences today

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM SWEDISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. Today, the 8[th] of April 2024, the subscription period in Diagonal Bio AB’s ("Diagonal Bio" or "the Company") issue of units consisting of shares

Read original

InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2023

April 8, 2024 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2023. The Annual Report is attached as a PDF and is available on the company’s website, https://www.indexpharma.com/en/financial-reports/.The Annual Report is mailed to shareholders and other stakeholders who specifically request it. Send request to info@indexpharma.com, or by mail to InDex Pharmaceuticals Holding AB (publ), Berzelius väg 13, 171 65 Solna, Sweden. For more information:Jenny Sundqvist, CEOPhone: +46 8 122 038 50E-mail: jenny.sundqvist@indexpharma.com Johan Giléus, CFO

Transaction in Own Shares

    08 April 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |05/04/2024|+-------------------------------------------------------------

Balder publishes Annual and Sustainability Report 2023

Fastighets AB Balder has summarised the fiscal year of 2023. The Annual and Sustainability Report, providing an overview of the group's progress towards financial and sustainability goals, is now available on the company's website.With a diversified property portfolio and high adaptability as a foundation, Balder consistently works broadly and purposefully to stand resilient. This was also the case in 2023. “2023 was in many ways similar to 2022. There is still turmoil in the external environment, contributing to continued global uncertainty. As a company, we are constantly adapting to

There are no items matching the current filter
There are no more items matching the current filter
Back to top